Navigation Links
Groundbreaking Consensus Statement Provides a Road Map for Treating Melanoma Patients with Cancer Immunotherapy
Date:8/27/2013

rd set of guiding principles for oncologists set forth for the effective and efficient application of cancer immunotherapy for patients with melanoma,” Howard L. Kaufman, MD, FACS, Rush University Medical Center and corresponding author on the paper said. “The group of authors who developed this statement considered the strength of the evidence for key issues in the field and provided consensus recommendations in these areas; especially where data was weak or missing.”

This consensus statement was created from work done by the SITC Cancer Immunotherapy Guidelines (CIG) Task Force established in 2010 and made up of more than 30 experts in the field of melanoma. The task force utilized the 2011 Institute of Medicine’s “Standards for Developing Trustworthy Clinical Practice Guidelines” to assure a fair, transparent and balanced process for the consensus statement. However, as cancer immunotherapy continues to rapidly develop, the SITC Melanoma CIG Task Force will update the consensus statement as new findings and results from on-going clinical trials or as the approval of drugs from the FDA for the treatment of melanoma are released.

To read “The Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma,” visit: http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2013.153.html.

For more information on the consensus statement and the Society for Immunotherapy of Cancer, visit: http://www.sitcancer.org/about-sitc/initiatives/cancer-immunotherapy-guidelines.

Read the full story at http://www.prweb.com/releases/2013/8/prwe
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
4. Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
5. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
6. JTCC researchers play important role in groundbreaking study that may change transplant practices
7. MyPuress Releases Details About Groundbreaking New Product
8. Rectal microbicide research takes giant leap forward with groundbreaking educational video
9. Skin Authority Creates One-of-a-Kind Solution for the One Billion People Worldwide Who are Vitamin D Deficient -- Groundbreaking Launch of "Inside Out" System
10. Groundbreaking Training Video Prepares Surgical Team to Become Safest in the U.S.
11. Groundbreaking UK study shows key enzyme missing from aggressive form of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... been recognized in the 2015 Aster Awards national competition for a marketing communications ... Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. , A ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held ... have to. , Instead of risking containment — or even destruction — of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital Tampa ... that was developed for targeted delivery of fluids to selected sites in the ... Florida Hospital Tampa with the device that provides direct, local delivery of chemotherapy ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... in Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National ... Thursday, September 17th at Ford Field in Detroit and the second match will occur ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2
... for years about the health risks of using the Chicago ... Chicago study, canoeing, kayaking, rowing, boating and fishing on the ... performing these same activities on other local waters -- a ... for swimmers at Lake Michigan beaches. The study is ...
... is providing a new route to get to and remove ... natural hole behind the molars, above the jawbone and beneath ... surgery, published in the October the Laryngoscope , the ... faster recovery and fewer complications than traditional approaches. And, because ...
... Oct. 25 (HealthDay News) -- ,Marijuana causes disruptions in ... people with schizophrenia, according to a new study. ... neurons in the brains of rats given a drug ... of marijuana. The effects of the drug on ...
... A new potential leukemia therapy targets only cancer cells, ... treatments affect cancer cells and healthy cells, causing significant ... and depression. This research is being presented at ... Meeting and Exposition in Washington, D.C., Oct. 23 ...
... TUESDAY, Oct. 25 (HealthDay News) -- Scientists have identified mutations ... have a potentially fatal blood clot after undergoing heart stent ... the drug Plavix (clopidogrel), a widely used blood thinner, and ... Oct. 26 issue of the Journal of the American ...
... Sox and Yankee fans alike sitting inches away from the television, ... away It might have been that very moment in 2003 when ... it might have been that very moment in 2004, when Boston,s Pokey ... devastation of 2003 began to fade from the memories of so many ...
Cached Medicine News:Health News:Boaters' risk of illness on Chicago River similar to other waterways 2Health News:Boaters' risk of illness on Chicago River similar to other waterways 3Health News:New 'scarless' surgery takes out tumors through natural skull opening 2Health News:Genes Could Highlight Plavix Users at Clot Risk After Stent 2Health News:A World Series to remember? 2
(Date:7/31/2015)... -- RnRMarketResearch.com adds Syringes and Needles ... provides an overview of syringes and needles currently ... databases, secondary and primary research. Complete ... spread across 124 pages, talking about 13 companies ... figures is now available at http://www.rnrmarketresearch.com/syringes-and-needles-pipeline-review-2015-market-report.html ...
(Date:7/31/2015)... Fla. , July 31, 2015  Xcelience, ... today that it has made a structured cash ... -based company specializing in milling, micronization and powder ... will help grow Powdersize,s business while simultaneously adding ... to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... and SAN DIEGO , July ... parent company Eisai Co., Ltd. (Headquarters: Tokyo ... "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: San ... Helen Torley , "NASDAQ: HALO") have signed a clinical ... Halaven ® , "eribulin") in combination with Halozyme,s investigational ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... alvespimycin, the company,s second-generation Hsp90 inhibitor, in,patients with ... to disrupt the activity of multiple oncogenes,and cell ... a,key signaling pathway in breast cancer. The objective ...
... study conducted in MDS - Vidaza therapy confers highly significant 9.4 ... to conventional care regimens, - Two year overall survival rate of 50.8% ... ... Pharmion Corporation,(Nasdaq: PHRM ) today announced the submission of a ...
Cached Medicine Technology:Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 2Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 3Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 2Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 3Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 4Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 5Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 6Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) 7
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: